End of life is an unfortunate but inevitable phase of the heart failure patients' journey. It is often preceded by a stage in the progression of heart failure defined as advanced heart failure, and characterised by poor quality of life and frequent hospitalisations. In clinical practice, the efficacy of treatments for advanced heart failure is often assessed by parameters such as clinical status, haemodynamics, neurohormonal status, and echo/MRI indices. From the patients' perspective, however, quality-of-life-related parameters, such as functional capacity, exercise performance, psychological status, and frequency of re-hospitalisations, are more significant. The effects of therapies and interventions on these parameters are, however, underrepresented in clinical trials targeted to assess advanced heart failure treatment efficacy, and data are overall scarce. This is possibly due to a non-universal definition of the quality-of-life-related endpoints, and to the difficult standardisation of the data collection. These uncertainties also lead to difficulties in handling trade-off decisions between quality of life and survival by patients, families and healthcare providers. A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality-of-life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-oflife assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effects of current i.v. vasoactive therapies such as inotropes, inodilators, and vasodilators on quality-of-life in advanced heart failure patients were analysed.
Introduction
Advanced heart failure (AdHF) is a malignant disease by nature [1] . It is characterised by a debilitating late course, with increasingly frequent hospitalisations and considerable morbidity besides the obvious mortality [2] . Heart failure affects quality of life (QoL) more profoundly than many other chronic diseases [3] . Even though QoL is a major concern, it appears that clinical management as well as research efforts do not focus sufficiently on this aspect. There is no good universal understanding of QoL in clinical practice [4] . Moreover, clinical trials often lack the assessment of relevant parameters, let alone using them as endpoints. Methods used are often subjective nonparametric measures either by patient or treating physician. In AdHF, daily variation is high and challenging for statistical analysis. Changes in echocardiographic or laboratory parameters indeed represent quantifiable outcomes, but they do not necessarily improve the daily life of the study participants, which is related to variables less easy to be quantified, such as self-care [5] . Also, QoL is by itself frequently variable in heart failure patients experience sometimes for reasons independent from the clinical conditions of the patient.
Treatment generally aims at reducing mortality, but longevity might well be an overrated goal in the management of AdHF. If the patient has to choose between prolongation of life and maintaining acceptable QoL, the choice is not always obvious. For example, some patients might decide against the implantation of an implantable cardiac defibrillator (ICD), even though they know that this choice can shorten their survival [6, 7] , when sudden death is foreseen as the most desirable outcome. Also, decisions can change over time, depending on the feelings of the patients and their families. As yet, there is only little data to shed light on this trade-off.
Finally, when AdHF patients experience a decompensation and are hospitalised they often receive, on top of the optimal treatment with ACEi/ARB, β-blockers, and aldosterone-antagonist, some i.v. vasoactive treatment, i.e. inotropes, inodilators, and vasodilators. There seems to be scarce evidence on the effect of these i.v. treatments for hospitalised AdHF patients on short-or long-term QoL.
A panel of 34 experts in the field of cardiology, intensive care medicine, and cardiovascular pharmacology from 21 countries (Austria, Brazil, Colombia, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, Israel, Italy, Mexico, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, and Ukraine) convened in Munich on January 23, 2015 for reviewing the existing data on QoL in patients with AdHF, and for discussing and reaching a consensus on the validity and significance of QoL assessment methods. Gaps in routine care and research, which should be addressed, were identified. Finally, published data on the effect of non-pharmacologic and pharmacologic treatments on QoL in AdHF patients were analysed.
Definition of QoL
QoL is not well defined in chronic heart failure and even less so in acute heart failure. None of the guidelines specify this outcome. Apparently, some aspects such as depression and social function disability, which are shown to have a significant impact on health-related QoL in patients with heart failure [8] , are not taken into consideration to a satisfying degree. Other factors affecting QoL and functionality comprise persistent congestion, neurohormonal/inflammatory activation, reduced peripheral muscle blood flow/myopathy, reduced kidney function, and right ventricular dysfunction, along with severely compromised haemodynamic state, which lead to cachexia. The inflammatory activation present in heart failure has been shown to correlate with QoL [9] . Moreover, QoL decreases as New York Heart Association (NYHA) functional class worsens [10] . Finally, exercise intolerance is a key factor.
Most of the available quality-of-life scores, such as the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the Kansas City Cardiomyopathy Questionnaire (KCCQ), are related to three major dimensions: physical, emotional, and social. Indeed, the data on available treatments commonly relate to the effects of therapy on these dimensions, but they are often rendered as the overall QoL scores without a thorough discussion of the individual domains.
Assessment of QoL
Besides objective surrogate measurements, various subjective methods can be used to assess the QoL in patients with heart failure, depending on whether their condition is acute or chronic (Table 1) . A pilot study suggests that health-related quality-of-life measures can be reliably collected using internet-based software [11] . Data collected in this manner are valid and of comparable quality to self-reported data Table 1 Current methods to assess the QoL in acute and chronic heart failure.
Acute heart failure • Visual analogue scale • Likert scale (both by patient or physician)
• Surrogate measures of dyspnoea index, BNP levels, lung function according to peak expiratory flow measures, and others. Chronic heart failure • Web-based possibilities to ask patients how they feel (questionnaires) • Standard questionnaire: Minnesota living with heart failure (MLHF) • Standard questionnaire: Kansas city cardiomyopathy questionnaire (KCCQ) • 6 min walking test is also used as an indicator of QoL or quality of performance • New York Heart Association functional class • RAND-36 general health survey (computer-based, requires the patient to be able to use the system) obtained via paper survey. Further validation and development is needed. Assessment methods of QoL in acute and advanced chronic heart failure vary because of the time-frame factor: e.g. short term ameliorations in dyspnea are one of the typical parameters followed in patients hospitalised for acute heart failure [12] , while the walking test is considered of importance in advanced heart failure patients.
QoL assessment in acute heart failure
While the visual analogue scale (VAS) offers absolute assessment of symptoms such as dyspnoea (endpoint: AUC over 5 days), the Likert scale focuses on relative assessment (endpoint: moderate/marked improvement at 6, 12, and 24 h) [13] . These scales have been used widely in acute heart failure trials. However, benefits conferred by the treatment are often hard to demonstrate. A commendable approach might be the inclusion of patients in studies early on, followed by monitoring of their changes in dyspnoea over time.
In the acute setting, symptoms such as congestion and clinical assessment of other heart failure signs are crucial, as they will also define the patient's QoL after hospital discharge. There is a consensus that, after hospital stay, patients should be followed up not only in terms of their disease trajectory, but also concerning their QoL. Dyspnoea scores in the acute phase and self-reported outcomes after one month of discharge are recommended as the instruments of choice. In the acute setting, dyspnoea is a compromised measure as it is subjective and hampered by hospital environment, extra administration of oxygen, infections, poor lung function and even positioning of the patient in bed rest. Dyspnoea scores as an index parameter should be evaluated as early as possible during hospitalisation as a parametric measure of therapeutic efficacy.
Due to its significance for adverse events and treatment compliance, depression is an important aspect. However, there are no reliable tools available to estimate depression in the acute phase. Many of the instruments are based on self-rated questionnaires, while the diagnostic gold standard is actually the interview with the specialist. Mental state is affected by the degree of dyspnea, congestion and even hyponatremia, when present [14] .
QoL assessment in chronic heart failure
In a pivotal study assessing the impact of AdHF on QoL in 79 patients hospitalised with HF in Sweden, patients were found to be significantly more affected by detrimental effects on sleep and energy than patients with stroke, as measured with the Nottingham Health Profile (NHP) ( Fig. 1 ) [15] . Both ESC and AHA highlighted the importance of patient reported outcomes in heart failure by publishing recently two recommendations at this regard [16, 17] .
In chronic heart failure, the MLHFQ and the KCCQ are standard assessment instruments, with the KCCQ being the most popular for use in clinical studies. There are some differences between these two that are elucidated in Table 2 [18] .
The KCCQ, followed by the NYHA classification and the 6-minute walk test, was found to reflect clinical changes in patients with heart failure most accurately [19] . Correlation coefficients for social, functional and physical areas are higher with the KCCQ than with the MLHFQ. Moreover, a more precise correlation of the KCCQ with survival has been established [9] .
These scores have some limitations, however. For instance, reduced functional capacity is not sufficiently covered by the KCCQ. The NYHA classification might also be less than optimal, because it was developed in 1970s in patients that differed from today's typical population.
Apart from questionnaires, when surrogate measures are called for, exercise capacity can be evaluated by the use of the 6-minute walk test or the cardiopulmonary exercise test. The latter is more accurate and reproducible than the 6-minute walk test, but less practical for everyday use. Finally, psychological distress is a high risk in this vulnerable patient group [20] . A holistic test that explores the physical, psychological and social aspects alike is the assessment of the patient's sexual satisfaction [21] .
Rehospitalisation
While mortality neither reflects disease burden nor disease progression, because heart failure progresses stepwise, rehospitalisation rate is a comprehensive measure of these outcomes. The length of hospital stays has generally decreased over time in heart failure patients, but readmission rates have essentially remained unchanged [22] . After discharge, approximately 50% of all patients are readmitted within six months. Re-hospitalisation within 30 days occurs in 25% of cases. The readmission rate increases from initial discharge to death with a high ratio of preventable readmissions in the initial phase [23] . As Fig. 2 shows, the risk for readmission is highest immediately following discharge and just before death.
Rehospitalisation as a measure of QoL
Congestion is the most frequent cause of readmission. Other factors associated with increased risk of readmission include higher age, comorbidities, premature discharge and noncompliance. Hospitalisation satisfies the demands of true surrogate endpoints, but it is also an endpoint in itself. It is easy to identify and easy to quantify. Time to first hospitalisation, frequency of hospitalisations, and duration of hospital admissions can be assessed. Another dimension that matters from the patient's point of view could be the number of days out of hospital as a possible interpretation of QoL. Early readmission is associated with worse long-term outcomes and significant increases in heart-failure-related health costs. With each readmission, QoL declines [24] . However, the established questionnaires of QoL hardly assess hospitalisation frequency.
Rehospitalisation as a measure of quality of care
At the same time, readmissions can be perceived as a parameter of quality of care. Hospitals frequently fail to implement strategies commonly recommended to reduce rehospitalisation [25] . Heart failure admission rates were demonstrated to vary considerably between institutions [26] . Readmission, however, is not necessarily a sign of failure, as higher rates could be a consequence of successful care. Patients who die during their index episodes can, in fact, never be readmitted [27] . Also, some elective readmissions for enhancement of medical care or interventions, including implantable device therapies, may represent appropriate care that reduces mortality.
HF management programmes
Improved outcomes have been achieved in outpatients discharged from the emergency department with early collaborative care (care provided by a primary care physician and a cardiologist) [28] . Patient management in multidisciplinary heart failure treatment centres that includes remote monitoring and self-treatment at home is deemed capable of lowering readmission rates [23] . As rehospitalisation often occurs early, the panel feels that re-evaluation of the patient by the heart failure nursing staff or the treating physicians in the first two weeks after discharge would be important.
Several strategies are associated with lower risk-standardised 30-day readmission rates (RSRR): [29] • Partnering with community physicians or physician groups to reduce readmission; • Partnering with local hospitals to reduce readmissions; • Having nurses responsible for medication reconciliation;
• Arranging follow-up appointments before discharge;
• Having a process in place to send all discharge papers or electronic summaries directly to the patient's primary physician; • Assigning staff to follow up on test results that return after the patient is discharged.
The number of selected strategies implemented was found to correlate with the RSRR.
The role of therapy in the improvement of QoL
Treatment goals naturally differ according to the setting. In acute heart failure, survival is considered predominant over QoL due to the irreversibility of death. In this line, the panel feels that more efficacious interventions for decongestion and improvement of haemodynamic measures are needed, as the hospitalisation rates remain high. However, even in the acute setting, several aspects of QoL, such as depression, deserve heightened attention and should not be neglected, as mental state may be a significant factor for treatment compliance. More research is required on the effects of acute heart failure therapies on QoL.
Depression is certainly one of the most important factors determining QoL in heart failure patients [8] . Its prevalence in acute and chronic heart failure is estimated at 35% to 60% and 11% to 25%, respectively [30] . An OPTIMIZE-HF analysis revealed that history of depression is a predictor of length of hospital stay and post-discharge mortality [31] .
Previous studies have suggested that their use can be associated with an increased likelihood of death and cardiovascular hospitalisation due to adverse pharmacodynamics effects [32] . Because depression has also been shown to be associated with increased mortality in these patients, it remains unclear if this association is due to the use of antidepressants or to depression [33] .
Special attention regarding the quality-of-life issues is required in the "palliative setting". Palliative care is by definition meant for malignant states with known short life expectancy. It is commendable in AdHF patients to prefer the term of "end-of-life" care. As opposed to the management of cancer patients, the length of this stage is hard to predict in the heart failure setting, particularly with current traditional HF classifications by NYHA classification and the ACC/AHA staging. In fact, conventional nosology for the staging of heart failure has a number of limitations, among which the inaccuracy in predicting the "end-oflife" heart failure stages [34] . As well known, heart failure per se is not confined to the heart, but it is a multiple-organ disease [35] . A new staging system for heart failure, named HLM, has been proposed [36, 37] , which could be useful in assessing the true "end-of-life" stage heart failure patients in order to apply palliative care and to enhance QoL of these individuals.
We should be more accurate in identifying HF patients with signs of multi organ failure in the early phase of the disease, during rehospitalisations and during outpatients follow-up. Early organ protection and organ support in AdHF (liver, kidney, central nervous system) is of the outmost importance for early and/or more appropriate treatment or for identifying patients needing cyclic hospital treatment to improve HF condition and QoL.
Pharmacological therapy
Medical treatment aiming at improving haemodynamic and QoLrelated outcomes such as congestion, cardiac output, cardiac index, right ventricular failure in hospitalised AdHF patients are described in the literature. When AdHF patients experience a decompensation and are hospitalised they often receive, on top of the optimal treatment with ACEi/ARB, β-blockers, and aldosterone-antagonist, some i.v. vasoactive treatment, i.e. inotropes, inodilators, and vasodilators. According to the AHA/ACC guidelines [38] , inotropes and vasodilators are viable pharmacological options for advanced chronic heart failure. The effects of intermittent or repetitive doses of inotropes, vasodilators and inodilators in AdHF patients have been described, both for a mere palliative aim and also as a bridge to transplant. Their effects on surrogate endpoints related to QoL have been also described, albeit with big gaps for important parameters such as depression (Table 3) . We hereby review the documented effects of established inotropes, inodilators, and vasodilators on QoL-related parameters in AdHF patients.
Dobutamine
Dobutamine has been used in chronic or repetitive fashion on patients with AdHF [42] . However, it was documented that dobutamine causes tachyphylaxis [43] , and its use in heart failure has been associated with increased mortality [44] . In a comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure, dobutamine was considered more attractive also due to a better economic impact [45] .
Milrinone
Continuous intravenous milrinone therapy has been administered at home in selected patients with advanced heart failure who are listed for transplant [46] . Some evidence was collected on the fact that this phosphodiesterase inhibitor reduces the number of hospitalisations and decreases the overall treatment costs of acute heart failure [47] . However, despite its beneficial haemodynamic actions, long-term therapy with oral milrinone was shown to increase the morbidity and mortality of patients with severe chronic heart failure [48] . Also the Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study does not support the routine use of intravenous milrinone as an adjunct to standard therapy in the treatment of patients hospitalised for an exacerbation of chronic heart failure [49] .
Levosimendan
Recent systematic reviews and meta-analyses reported that the calcium sensitizer levosimendan conveys benefits that are relevant for the patient's QoL [50, 51] . In a study by Parissis et al., functional capacity and scores of emotional stress favoured levosimendan over placebo [52] . Trials assessing the effects of repetitive administration have yielded improvements regarding functional capacity, left ventricular ejection fraction, and quality-of-life scores [53] [54] [55] . Potential explanations for these effects relate to levosimendan-mediated, sustained reductions in inflammatory cytokines and apoptotic factors [56, 57] . Furthermore, levosimendan treatment decreases oxidative stress, prevents oxidative damage, and improves endothelial function as well as right ventricular function [58] [59] [60] . Improving of right ventricular function is especially important in AdHF with signs of right ventricular failure since ascites, oedema and liver or kidney dysfunction have an important impact on QoL. Brain natriuretic peptide (BNP) levels and inflammatory markers are reduced in comparison to placebo [61] . In the REVIVE II trial an improvement in dyspnoea by levosimendan as compared to placebo was shown [62] . In the LevoRep trial, the effects of repetitive levosimendan infusions on 6-minute walk test, KCCQ clinical summary score, and event-free survival were described [63] In a recent comparison with dobutamine, levosimendan significantly reduced re-hospitalisation rates and shortened the length of hospital stay in acute heart failure by 1.5 days [64, 65] .
Nitroprusside
Nitroprusside was shown to be more effective than dobutamine in patients with end-stage heart failure awaiting heart transplantation [42] . In patients with advanced, low-output heart failure, vasodilatory Table 3 Effects of inotropic and vasoactive therapies currently used in clinical practice on outcomes in AdHF patients.
Hemodynamics
Neuro-hormons QoL-related parameters Survival
n.d. = no relevant data obtained by cross-searching PubMed for ("parameter" and "active compound"[ti]). a Indirect effect. b According to Fedele et al. [64] . c According to Lewis et al. [39] . d According to Mullens et al. [40] . e According to O'Connor et al. [41] . f According to Parissis et al. [52] . g According to Capomolla et al. [42] (vs. nitroprusside). h According to Packer et al. [48] . i According to the meta-analyses by Nieminen et al. [50] and Silvetti et al. [51] . j According to Reed et al. [68] .
therapy with sodium nitroprusside used in conjunction with optimal current medical therapy during hospitalisation might be associated with favourable long-term clinical outcomes [40] .
Nesiritide
The effects of nesiritide on mortality and quality of life of AdHF patients were studied in the two FUSION clinical trials [66, 67] , which gave promising but not definitive answers, the authors warranting for a definitive phase III mortality/quality of life trial. In the ASCEND-HF trial, it did not significantly influence medical resource use or health utilities compared with standard care alone [68] .
Drugs under development
Data on the effect on QoL parameters by the treatment of AdHF patients with vasodilators under clinical development such as carperitide, serelaxin, and ularitide have been also published in the literature.
Carperitide was also used intermittently in outpatients with AdHF. However, the experience is very limited here [69] .
Serelaxin, a vasoactive peptide hormone, was shown to give rise to a significant but clinically small improvement in dyspnoea over placebo according to the VAS scale, but not according to the Likert scale in the RELAX-AHF trial [70] . The 180-day mortality was slightly but significantly reduced. A sub-analysis revealed that benefits for both Likert and VAS dyspnoea evaluation are seen in patients with preserved left ventricular ejection fraction [71] .
Ularitide, a synthetic natriuretic peptide hormone, is also capable of improving dyspnoea and BNP levels [72] . A currently ongoing phase 3, randomised, double-blind, placebo-controlled study in patients with acute heart failure will provide additional 6 month morbidity and mortality evidence.
Non-pharmacological therapy
Physical training is an important component of heart failure management, even if the severity of the disease creates limitation in the adherence of patients to exercise programmes [73, 74] .
Further, devices such as biventricular pacemakers for cardiac resynchronisation therapy (CRT) and mitral clips for severe mitral insufficiency could always be considered in appropriate heart failure patients. In fact, AdHF patients often experience atrial fibrillation, which necessitates expert care on heart rate control [75] . More recent advancements were reviewed elsewhere [76] .
Although CRT-P that enhances QoL should be maintained, at the end-of-life ICDs frequently deliver multiple shocks, which is a matter of anxiety and poor QoL for patients and carers, and should be deactivated [77, 78] .
Further, tele-monitoring of patients discharged after heart failure exacerbation is an important addition and was shown to be costeffective [79] . Finally, non-compliance with non-pharmacological recommendations in heart failure patients, was clearly associated with adverse outcome [80] .
Trade-off survival vs. QoL
Postponing death is a treatment goal apart from symptom relief. Under certain circumstances, however, if life-prolonging measures are expected to impair QoL, a choice has to be made between these two. Recently, Eschalier and co-workers tried to give an answer to the question if there is any benefit in optimising heart failure treatment in over-80 year-old patients with their study HF-80 [81] . Several trials investigated the topic of end-life-preferences in heart failure patients, with conflicting results [7] . While preferences remained in favour of survival for many patients despite AdHF symptoms in the study by Stevenson et al. [82] , Kraai et al. found that the majority of patients attach more weight to QoL over longevity [6] . Another trial identified two distinct groups of patients, one preferring treatments that prolonged survival time and another that favoured strategies that improved QoL but reduced survival time [7] . These treatment preferences were independent of functional or symptomatic status, suggesting that they may be decided early in the course of illness. Formiga et al. stated that advance planning of end-of-life procedures and doctor-patient communication regarding these items remain poor and must be improved [83] . Finally, heart failure patients' own requests to forego resuscitation should be considered. Dev et al. stated that these requests may reflect preferences for intervention to enhance quality rather than prolong survival, which is particularly important as these patients have high early mortality [84] .
Future research with focus on QoL
The inclusion of QoL or QoL-related parameters as clear primary endpoint in future trials is strongly advocated. An important aspect that should be elucidated is risk stratification that allows for the ideal timing of patient discharge from hospital in order to avoid early readmission. Also, validation of simple instruments such as the VAS would be called for to facilitate their use in clinical practice. Up to date, there are few but promising studies evaluating the safety and efficacy of antidepressants in acute heart failure [85] . Future trials are also required to assess the utility of treatments for depression and their safety profiles. This is of growing importance considering the advancing average age of heart failure patients, in whom drug-drug interactions and compliance issues pose a challenge.
Conclusion
Heart failure adversely affects QoL, and its deterioration appears to be related to poor long-term prognosis. QoL is influenced by a multitude of factors derived from the physical, emotional and social situation of the patient, which is why it cannot be categorised easily. Comprehensive team approaches are of uppermost priority for many patients and their relatives/caregivers, particularly in the end-of-life setting.
It appears that the available instruments of assessment require refinement with the aim of greater practicability in daily routine. Also, QoL is frequently missing as an endpoint in clinical studies on AdHF patients, even though it doubtlessly offers merits as a measure of efficacy of treatment.
An issue which has not been debated well enough in the literature or in the clinical societies is the trade-off of survival vs QoL. It still seems a taboo to admit that very often this is a matter of choice for patients, families, and doctors, and that survival is not the clear answer [6, 7] . It remains therefore puzzling that demonstrating advantages on long term survival for new drugs to be used in the acute phase of AdHF is still a requirement in regulatory clinical trials, while improvement of QoL are not.
However, we are comforted by a recent report by Pani and coworkers [86] where methods are advocated for the validation of patient reported outcomes and measurements of well-being. We agree also with those authors that the evaluation of 'real-life' treatment effectiveness and of health as a value would help in the development of drugs which take into account the "patient-perspective".
In hospital drug therapy as well as non-pharmacological out-ofhospital strategies should be adjusted according to QoL goals. In this way it should be possible to also prevent unplanned frequent readmissions, which are a common burden in the end-of-live stage of patients with AdHF. Finally, the panel went through the sparse and controversial evidence on the effects on QoL of i.v. inotropes and vasodilators used during hospitalisation of AdHF patients. Among the drugs already used in clinical practice, encouraging advantages were reported in the literature for the inodilator levosimendan. Promising vasodilators such as serelaxin and ularitide could also prove useful in the near future.
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